Preparation method of key intermediate of medicine for treating ulcerative colitis
The preparation of high-purity eltromod ethyl ester through cyclosynthesis and reduction reactions has solved the problems of low yield and high cost of eltromod synthesis in the prior art, and achieved efficient and low-cost preparation of eltromod intermediates , with environmentally friendly characteristics.
Patent Information
- Application Number
- CN202410964678.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-12
AI Technical Summary
The existing Eltmode synthesis route has lower yields and higher costs due to chiral splitting steps.
(E/Z)-2-(2-oxocyclopentyl)acetate is used to cyclosynthesis reaction with the compound of formula a, and then the intermediate is prepared by reducing reaction (R/S) etrmod ethyl ester. Eltrimod was obtained by enzymatic hydrolysis or chiral column resolution, and tetraethyl orthosilicate, pyridinium salt and organic base were used as catalysts to selectively hydrogenate the reducing agent to improve the reaction efficiency.
High yield preparation of high-purity Eltromod key intermediates is achieved, reducing production costs, and improving environmental friendliness by optimizing the process route.
Smart Images

Figure CN118930474A_ABST
Abstract
Description
Field of the Invention
[0001] The invention belongs to the field of chemical drugs, and specifically relates to a new preparation method of a key intermediate (R / S) eltramod ethyl ester of eltramod, a drug for treating ulcerative colitis. Background Art
[0002] Ulcerative colitis (UC), also known as nonspecific ulcerative colitis, is a chronic disease that causes inflammation and ulcers in the colon and rectum. The main symptoms during an attack include abdominal pain and diarrhea with blood in the stool. Weight loss, fever, and anemia may also occur during an attack of ulcerative colitis. Usually, the symptoms develop slowly and vary in severity. The symptoms often appear intermittently, and there is often a symptom-free period between two attacks. Complications of ulcerative colitis may include megacolon or inflammation of the eyes, joints, or liver, as well as colon cancer.
[0003] The cause of ulcerative colitis is unknown. Theories regarding its cause include autoimmune disease, genetics, changes in the intestinal flora, and environmental factors. Some of the arguments for the higher incidence in developed countries are the hygiene hypothesis of lack of exposure to infectious agents, the introduction of Western diets, and differences in lifestyle. Early removal of the appendix may have some preventive effect. Diagnosis is typically by colonoscopy with biopsy. Ulcerative colitis is an inflammatory bowel disease that accompanies Crohn's disease and microscopic colitis.
[0004] Dietary changes can help, such as a high-calorie or lactose-free diet. Several medications are used to treat symptoms or relieve them, including aminosalicylates such as sulfasalazine, corticosteroids, immunosuppressants such as azathioprine, and biological therapies for inflammatory bowel disease. If the disease is severe, does not improve with treatment, or if complications such as colorectal cancer develop, a colectomy may be necessary. Proctocolectomy can cure the disease.
[0005] The prevalence of ulcerative colitis in China is about 11.6 / 100,000. Ulcerative colitis can occur at any age, but it most often occurs in young and middle-aged adults. The peak age in my country is 20 to 49 years old, and there is no obvious gender difference. Ulcerative colitis used to be very rare in my country, but with the development of my country's economy, ulcerative colitis has shown a rapid upward trend. Now ulcerative colitis has become a common disease.
[0006] Etrasimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of moderately to severely active ulcerative colitis in adults. The control of lymphocytes moving out of the lymph nodes and arriving at sites of gastrointestinal inflammation is controlled by the S1P1 receptor, and Etrasimod works by acting on the S1P receptor, which prevents immune cells (lymphocytes) from entering the large intestine, allowing more lymphocytes to remain in the lymph nodes, so fewer immune cells can travel to sites of inflammation, which helps relieve the symptoms of ulcerative colitis. Etrasimod has good safety and tolerability, and its launch provides a new drug option for the treatment of patients with moderately to severely active ulcerative colitis, reducing the risk of surgery.
[0007] The chemical structure of Itramod is as follows:
[0008]
[0009] The prior art document patent CN201810670853 reports the synthesis route of eltramod, which is as follows:
[0010]
[0011] This route uses (4-cyclopentyl-3-(trifluoromethyl)phenyl)methanol (Formula c) as the starting material, first undergoes a chlorination reaction to prepare the intermediate 4-(chloromethyl)-1-cyclopentyl-2-(trifluoromethyl)benzene, then undergoes a docking reaction with the material 2-(7-hydroxy-1,2,3,4-tetrahydrocyclopentadien[b]indol-3(4H)-ylidene)ethyl acetate (Formula b) to prepare the intermediate (R / S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentadien[b]indol-3-yl)ethyl acetate, and then undergoes a hydrolysis method using Candida antarctica lipase B to obtain eltromod. Due to the last step of chiral resolution, the yield of eltromod is low and the cost is high.
[0012] The patent also reports multiple synthesis methods of compounds of formula b and formula c, as follows:
[0013] Synthesis of compound of formula b:
[0014]
[0015] Synthesis of compound of formula C:
[0016] Summary of the invention
[0017] The object of the present invention is to overcome the deficiencies of the prior art and provide a method for preparing an ethyl (R)-2-(2-oxocyclopentyl)acetate intermediate of eltramod, the method comprising:
[0018]
[0019] Step 1, cyclization reaction of ethyl (E / Z)-2-(2-oxocyclopentylidene)acetate and the compound of formula a to prepare the intermediate ethyl (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetate;
[0020] Step 2, the intermediate (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetic acid ethyl ester is subjected to reduction reaction to prepare (R / S) eltramod ethyl ester;
[0021] The X group in the compound of formula a is chlorine, bromine or iodine, preferably bromine or iodine.
[0022] (R / S) Itramod ethyl ester can be further subjected to alkaline hydrolysis chiral column separation or enzymatic hydrolysis separation to obtain Itramod, as follows:
[0023]
[0024] The route of the present invention is different from the synthesis route of eltramod reported in the prior art document patent CN201810670853.
[0025] The purpose of the present invention is to provide a novel method for preparing a high-purity key intermediate (R / S) ethyl ester of eltramod through two-step reactions. In the route, the starting material (E / Z)-ethyl 2-(2-oxocyclopentylidene)acetate is cheap and easy to purchase, and the starting material compound of formula a can be quickly prepared by (4-cyclopentyl-3-(trifluoromethyl)phenyl)methanol and 4-amino-3-halophenol. The route of the present invention is significantly characterized by a short route, high yield, easy acquisition of starting materials, and environmental friendliness.
[0026] The catalyst for the cyclization reaction in step 1 of the present invention is tetraethyl orthosilicate (TEOS), a pyridinium salt, an organic base and palladium (II) acetate, wherein the orthosilicate is selected from tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate, preferably tetraethyl orthosilicate; the pyridinium salt is selected from pyridinium p-toluenesulfonate (PPTS), pyridinium methanesulfonate or pyridinium trifluoromethanesulfonate, preferably pyridinium p-toluenesulfonate; the organic base is selected from diisopropylethylamine, triethylamine or N-methylmorpholine, preferably diisopropylethylamine. In the cyclization reaction, the molar feed ratio of the control formula b compound, ethyl (E / Z)-2-(2-oxocyclopentylidene)acetate, orthosilicate, pyridinium salt, organic base and palladium (II) acetate is 1:1.1-1.5:0.02-0.06:2-4:0.02-0.05, preferably 1:1.3:0.04:3:0.03, which can ensure complete reaction and less by-products, and most of the unreacted materials and by-products can be removed by post-treatment and recrystallization operations.
[0027] In the hydrogenation reduction reaction of step 2 of the present invention, because the intermediate (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)ethyl acetate contains a benzyloxy group in its structure, it is easy to remove it in the hydrogenation reduction reaction. Selecting a suitable catalyst to selectively reduce the unsaturated olefins at the α and β positions of the carbonyl group is the key to the implementation of the present invention. After screening, our company finally selected 2-phenylpyridyl pentamethylcyclopentadienyl lawrencium (RhH-1) or benzo[h]quinolyl pentamethylcyclopentadienyl lawrencium (RhH-2) to achieve the purpose of the above-mentioned selective reduction, and has no effect on other groups. The use of the above rhodium catalyst is the biggest highlight of the present invention.
[0028] In the hydrogenation reduction reaction of step 2 of the present invention, the molar feed ratio of the intermediate (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)ethyl ester to the rhodium catalyst is 1:0.02-0.05, preferably 1:0.03. In addition, the pressure of the hydrogenation reaction is controlled to be 50-100 psi, which can ensure that the reaction is complete and the by-products are less. After simple post-treatment, high-purity (R / S) eltramod ethyl ester can be obtained.
[0029] The present invention provides a new route for synthesizing the key intermediate (R / S) eltramod ethyl ester of eltramod with short route, high yield and high purity. The method has obvious advantages over the prior art documents, can greatly reduce the production cost of eltramod, and can benefit from it. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 :Process route diagram of the present invention Specific implementation methods
[0032] The technical solutions in the embodiments of the present invention will be described in detail below in conjunction with the embodiments of the present invention. However, the following embodiments are only used to understand the present invention and cannot limit the present invention. The present invention can be implemented in a variety of different ways as defined and covered by the claims.
[0033] The following will further illustrate the synthesis method of eltramod and the advantages of the method in conjunction with Examples 1-8 of the present invention.
[0034] Example 1: Synthesis of 2-iodo-4-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)aniline (Formula aI)
[0035]
[0036] (4-cyclopentyl-3-(trifluoromethyl)phenyl)methanol (153.8 g, 0.63 mol), 4-amino-3-iodophenol (141.0 g, 0.6 mol), triphenylphosphine (165.2 g, 0.63 mol), diisopropyl azodicarboxylate (127.4 g, 0.63 mol) and 1.5 L of anhydrous tetrahydrofuran were added to an ultrasonic reactor, and the reaction was stirred at room temperature for 15 minutes under ultrasonic stirring. The reaction was terminated, and 1.8 L of ethyl acetate and 2.5 L of ethyl acetate were added. 0.5 mol / L hydrochloric acid, stirred and separated, the aqueous phase was extracted with 1.2 L of ethyl acetate, the pH of the aqueous phase was adjusted to 10 with 40% sodium hydroxide solution, 1.5 L of ethyl acetate was added to extract the aqueous phase, the organic phase was first washed with 1.2 L of 10% sodium bicarbonate solution, and then washed twice with water (1.2 L / time), dried over anhydrous sodium sulfate, concentrated to dryness under reduced pressure, and dried to obtain 2-iodo-4-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)aniline (Formula aI, 179.9 g, yield 65%), Ms m / z 462.1 (M+1).
[0037] Example 2: Synthesis of 2-bromo-4-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)aniline (Formula a-II)
[0038]
[0039] (4-cyclopentyl-3-(trifluoromethyl)phenyl)methanol (153.8 g, 0.63 mol), 4-amino-3-bromophenol (Formula aI, 112.8 g, 0.6 mol), triphenylphosphine (165.2 g, 0.63 mol), diisopropyl azodicarboxylate 127.4 g, 0.63 mol) and 1.5 L of anhydrous tetrahydrofuran were added to an ultrasonic reactor, and the reaction was stirred with ultrasonic wave at room temperature for 15 minutes. The reaction was terminated, and 1.8 L of ethyl acetate and 2.5 L of ethyl acetate were added. 0.5 mol / L hydrochloric acid, stirred and separated, the aqueous phase was extracted with 1.2 L ethyl acetate, the pH of the aqueous phase was adjusted to 10 with 40% sodium hydroxide solution, 1.5 L ethyl acetate was added to extract the aqueous phase, the organic phase was first washed with 1.2 L 10% sodium bicarbonate solution, and then washed twice with water (1.2 L / time), dried over anhydrous sodium sulfate, concentrated to dryness under reduced pressure, and dried to obtain 2-bromo-4-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)aniline (Formula bI, 164.0 g, yield 66%), Ms m / z 414.1 (M+1).
[0040] Example 3: Synthesis of (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetic acid 1
[0041]
[0042] 2-iodo-4-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)aniline (Formula aI, 138.4 g, 0.3 mol), ethyl (E / Z)-2-(2-oxocyclopentylidene)acetate (75.7 g, 0.45 mol), tetraethyl orthosilicate (TEOS, 81.3 g, 0.39 mmol), pyridinium p-toluenesulfonate (PPTS, 3.02 g, 12 mmol) and 900 ml of dimethylformamide were added to a dry three-necked flask, heated to 135±5°C and stirred for reaction for 4 h, cooled to 120°C, and diisopropylethylamine (DIEA, 116.3 g, 0.9 mol), palladium (II) acetate (2.03 g, 9 mmol) were added. mol), continue to control the temperature at 120±5℃ and stir to react for 5h, terminate the reaction, filter while hot, cool the filtrate to room temperature, add 2.2L of ethyl acetate and 1.8L of water, stir and separate, wash the organic phase with water twice (1.8L / time), dry over anhydrous sodium sulfate, and concentrate to dryness under reduced pressure. The residue is slurried with n-hexane twice (400ml / time), filtered, and the filter cake is recrystallized with a mixed solvent of ethyl acetate (150ml)-n-hexane (450ml), and dried to obtain (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indole-3(2H)-ylidene)acetic acid ethyl ester (101.5g, yield 70%), Msm / z 484.2(M+1), 1 H NMR (400 MHz, CDCl 3 ): δ1.23(t,3H),1.61-1.93(m,8H),2.05-2.19(m,2H),2.68-2.78(m,4H),4.10(q,2H),5. 16(s,2H),6.12(s,1H),7.01(d,1H),7.25(d,1H),7.63(d,1H),7.75(d,1H),7.76(s,1H).
[0043] Example 4: Synthesis of (E / Z)-ethyl 2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetate 2
[0044]
[0045] 2-Bromo-4-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)aniline (Formula a-II, 124.3 g, 0.3 mol), ethyl (E / Z)-2-(2-oxocyclopentylidene)acetate (75.7 g, 0.45 mol), tetraethyl orthosilicate (TEOS, 81.3 g, 0.39 mmol), pyridinium p-toluenesulfonate (PPTS, 3.02 g, 12 mmol) and 900 ml of dimethylformamide were added into a dry three-necked flask, heated to 135±5°C and stirred for reaction for 4 h, cooled to 120°C, and diisopropylethylamine (DIEA, 116.3 g, 0.9 mol), palladium (II) acetate (2.03 g, 9 mmol), continue to control the temperature at 120±5°C and stir to react for 5h, terminate the reaction, filter while hot, cool the filtrate to room temperature, add 2.2L of ethyl acetate and 1.8L of water, stir and separate, wash the organic phase with water twice (1.8L / time), dry over anhydrous sodium sulfate, and concentrate to dryness under reduced pressure. The residue is slurried with n-hexane twice (400ml / time), filtered, and the filter cake is recrystallized with a mixed solvent of ethyl acetate (150ml)-n-hexane (450ml), and dried to obtain ethyl (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indole-3(2H)-ylidene)acetate (100.1g, yield 69%), Msm / z 484.2 (M+1).
[0046] Example 5: Synthesis of (R / S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)ethyl acetate ((R / S) eltramod ethyl ester)
[0047]
[0048] Ethyl (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetate (96.7 g, 0.2 mol), 2-phenylpyridylpentamethylcyclopentadienyl (RhH-1, 2.36 g, 6 mmol) and 500 ml of methanol were added to a hydrogenation reactor, replaced with nitrogen, hydrogenated to 80 psi and stirred at room temperature. The mixture was stirred and reacted for 24 hours, the reaction was terminated, filtered, and the filtrate was concentrated to dryness under reduced pressure. The residue was dispersed with 200 ml of n-hexane by stirring, filtered, and dried to obtain (R / S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)ethyl acetate ((R / S) eltramod ethyl ester, 85.5 g, yield 88%), purity 97.8%, Ms m / z 486.3 (M+1), 1 H NMR (400 MHz, CDCl3 ): δ1.24(t,3H),1.60-1.79(m,4H),1.82-1.93(m,2H),2.04-2.18(m,2H
[0049] ),2.52-2.60(m,2H),2.62-2.82(m,4H),3.30-3.40(m,1H),3.49-3.58(m,1H),4.16(q,2H),5.17(s ,2H),6.80(dd,1H),7.00(d,1H),7.26(d,1H),7.62(d,1H),7.74(d,1H),7.75(s,1H),9.50(s,1H).
[0050] Example 6: (R / S) Synthesis of Eltramod Ethyl Ester 2
[0051]
[0052] Ethyl (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetate (96.7 g, 0.2 mol), benzo[h]quinolylpentamethylcyclopentadienyl (RhH-2, 2.51 g, 6 mmol) and 500 ml of methanol were added to a hydrogenation kettle, nitrogen was replaced, hydrogenated to 80 psi, stirred at room temperature for 24 h, the reaction was terminated, filtered, and the filtrate was concentrated to dryness under reduced pressure. The residue was dispersed with 200 ml of n-hexane by stirring, filtered, and dried to obtain (R / S) eltramod ethyl ester (81.6 g, yield 84%) with a purity of 97.2% and Ms m / z 486.3 (M+1).
[0053] Example 7: Preparation of Itramod 1
[0054]
[0055] (R / S) eltramod ethyl ester (24.3 g, 50 mmol), lithium hydroxide (1.44 g, 60 mmol) and 120 ml of tetrahydrofuran were placed in a three-necked flask, stirred at room temperature for 6 h, 200 ml of water and 180 ml of ethyl acetate were added, stirred and separated, the aqueous phase was extracted with 150 ml of ethyl acetate, 100 ml of ethyl acetate was added to the aqueous phase, and the pH was adjusted to 4.0 with concentrated hydrochloric acid, separated, the organic phase was washed with 150 ml of water, dried over anhydrous sodium sulfate, and distilled under reduced pressure. The residue was separated and purified by industrial chiral preparative chromatography, and the eluent was concentrated and dried to obtain R-configuration eltramod (18.1 g, yield 79%), chemical purity 99.1%, ee value 99.0%, Ms m / z 458.2 (M+1).
[0056] Example 8: Preparation of Itramod 2
[0057]
[0058] According to the enzymatic method in step G of Example 8 in CN201810670853, (R / S) itramod ethyl ester (24.3 g, 50 mmol) was hydrolyzed and resolved using Antarctic Candida lipase B in a phosphate solution system to finally obtain R-configuration itramod (17.6 g, yield 77%) with a chemical purity of 98.7%, an ee value of 99.4%, and Ms m / z 458.2 (M+1).
[0059] Compared with the synthesis route of the key intermediate (R / S) eltramod ethyl ester of eltramod reported in the prior art documents, Examples 1-8 of the present invention have a shorter route, a higher total yield, cheap and readily available starting materials, and are environmentally friendly, which is of great significance for the industrialization of eltramod.
[0060] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a key intermediate of a drug for treating ulcerative colitis, characterized in that: The method is: Step 1, cyclization reaction of ethyl (E / Z)-2-(2-oxocyclopentylidene)acetate and the compound of formula a to prepare the intermediate ethyl (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetate; Step 2, the intermediate (E / Z)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetic acid ethyl ester is subjected to reduction reaction to prepare (R / S) eltramod ethyl ester; The X group in the compound of formula a is chlorine, bromine or iodine, preferably bromine or iodine.
2. The preparation method according to claim 1, characterized in that: The catalyst for the cyclization reaction in step 1 is tetraethyl orthosilicate (TEOS), pyridinium salt, organic base and palladium (II) acetate, wherein the orthosilicate is selected from tetraethyl orthosilicate (TEOS) or tetramethyl orthosilicate, preferably tetraethyl orthosilicate; the pyridinium salt is selected from pyridinium p-toluenesulfonate (PPTS), pyridinium methanesulfonate or pyridinium trifluoromethanesulfonate, preferably pyridinium p-toluenesulfonate; the organic base is selected from diisopropylethylamine, triethylamine or N-methylmorpholine, preferably diisopropylethylamine.
3. The preparation method according to claims 1 and 2, characterized in that: In the step 1 cyclization reaction, the molar feed ratio of the compound of formula a, ethyl (E / Z)-2-(2-oxocyclopentylidene)acetate, orthosilicate, pyridinium salt, organic base and palladium (II) acetate is 1:1.1-1.5:0.02-0.06:2-4:0.02-0.05, preferably 1:1.3:0.04:3:0.
03.
4. The preparation method according to claim 1, characterized in that: A rhodium catalyst needs to be added in the reduction reaction of step 2, and the rhodium catalyst is selected from 2-phenylpyridyl pentamethylcyclopentadienyl lawrencium (RhH-1) or benzo[h]quinolyl pentamethylcyclopentadienyl lawrencium (RhH-2).
5. The preparation method according to claims 1 and 4, characterized in that: In the reduction reaction of step 2, the molar feed ratio of the intermediate (E / Z)-ethyl 2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,4-dihydrocyclopentyl[b]indol-3(2H)-ylidene)acetate to the rhodium catalyst is 1:0.02-0.05, preferably 1:0.
03.
6. The synthesis method according to claims 1, 4 and 5, characterized in that The pressure of the hydrogenation reduction reaction in step 2 is 50-100 psi.
